Detalhe da pesquisa
1.
Management of older patients with frailty and acute myeloid leukaemia: A British Society for Haematology good practice paper.
Br J Haematol
; 199(2): 205-221, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36000944
2.
A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.
Blood
; 125(25): 3878-85, 2015 Jun 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-25833957
3.
British Society for Haematology guidelines for the diagnosis and evaluation of prognosis of Adult Myelodysplastic Syndromes.
Br J Haematol
; 194(2): 282-293, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34137023
4.
British Society for Haematology guidelines for the management of adult myelodysplastic syndromes.
Br J Haematol
; 194(2): 267-281, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34180045
5.
Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial.
Haematologica
; 101(6): 724-31, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26921360
6.
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Lancet Oncol
; 16(13): 1295-305, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26384238
7.
The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML.
Br J Haematol
; 158(4): 519-22, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22639959
8.
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse.
Blood
; 114(19): 4027-33, 2009 Nov 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-19710500
9.
Routine management, healthcare resource use and patient and carer-reported outcomes of patients with transfusion-dependent ß-thalassaemia in the United Kingdom: A mixed methods observational study.
EJHaem
; 2(4): 738-749, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35845207
10.
Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses.
J Clin Oncol
; 39(8): 890-901, 2021 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33356418
11.
Quality-of-life issues and symptoms reported by patients living with haematological malignancy: a qualitative study.
Ther Adv Hematol
; 11: 2040620720955002, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33101618
12.
Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity.
Front Pharmacol
; 11: 209, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32210809
13.
Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO.
Front Pharmacol
; 11: 571066, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33192513
14.
Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study.
Front Pharmacol
; 11: 1308, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33013368
15.
Guidelines for the diagnosis and management of adult myelodysplastic syndromes.
Br J Haematol
; 164(4): 503-25, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24372298
16.
Paper and electronic versions of HM-PRO, a novel patient-reported outcome measure for hematology: an equivalence study.
J Comp Eff Res
; 8(7): 523-533, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31037971
17.
Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project.
Leuk Res
; 31(5): 599-604, 2007 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-16959316
18.
Drug evaluation: MGCD-0103, a histone deacetylase inhibitor for the treatment of cancer.
Curr Opin Investig Drugs
; 8(6): 485-92, 2007 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-17621879
19.
The addition of gemtuzumab ozogamicin to chemotherapy in adult patients with acute myeloid leukemia.
Expert Rev Anticancer Ther
; 16(4): 377-82, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26942450
20.
Considerations and challenges for patients with refractory and relapsed acute myeloid leukaemia.
Leuk Res
; 47: 149-60, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27371910